A Phase I/II Study of the Safety and Immunogenicity of a Recombinant Human Parvovirus B-19 Vaccine

Trial Profile

A Phase I/II Study of the Safety and Immunogenicity of a Recombinant Human Parvovirus B-19 Vaccine

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2011

At a glance

  • Drugs MF 59; Parvovirus vaccine
  • Indications Parvovirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Status changed from suspended to completed, according to ClinicalTrials.gov.
    • 17 Apr 2008 The expected completion date for this trial is now 1 Sep 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top